Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hospira rolls out Gemcitabine HCL for injection
Hospira‘s Gemcitabine is approved by the US Food and Drug Administration (FDA) for treatment of a variety of cancers. Hospira claimed that it will be the first company
Hospira‘s Gemcitabine is approved by the US Food and Drug Administration (FDA) for treatment of a variety of cancers. Hospira claimed that it will be the first company
DelRx has proprietary platform drug delivery technology for transmucosal administration of large molecule drugs as a liquid dispersion, e.g., peptides like insulin, monoclonal antibodies, hormones, vaccines and other
Sunesis Pharma said that Vosaroxin is an anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. According
Cielo chief medical officer Donald Nease said that in Phase I, they successfully studied and documented the needs and expectations of primary care practices and providers regarding web-based
Chiltern said that SAFE is a complete electronic Trial Master File (TMF) solution which facilitates remote management of documents, which saves administrative time and increases accuracy and security
The acquisition is likely to enhance ITT’s Analytics business, formed earlier this year with the acquisition of Nova Analytics. ITT Analytics is a manufacturer of field, portable, laboratory
Under the terms of the collaboration, which is supported by a grant from the UK East Midlands Development Agency, London Genetics and Astrimmune will put together a proposal
Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout Chinese Hamster Ovary (CHO) cell line as
ARYx‘s loss from operations was $2.15m, compared to $7.63m for the comparable period in 2009. For the nine months ended 30 September 2010 ARYx posted a net loss
According to AP Pharma, the net loss was higher in the current fiscal quarter primarily due to $1m of income recognised in the prior year quarter in connection